Completion of the offering is subject to pricing, standard closing and market conditions, and other factors.
After paying fees and expenses, Tenet will use net proceeds from the sale for “general corporate purposes” such as debt repayment and refinancing, cash on balance sheet, working capital and capital expenditure.
Tenet will secure the notes maturing in 2028 on a first-lien priority basis by pledging ownership interests of certain subsidiaries. The notes will be “senior to Tenet’s existing and future indebtedness secured on a more junior basis.”
Click here for more information.
More articles on ASCs:
The ‘new normal’ for ASCs: 16 admins on how the pandemic will change the field forever
Dr. Thomas Vikoren: Same-day TJR ‘made all the more important’ by COVID-19
Indiana orthopedic practice with surgery center to open
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
